Squarepoint Ops LLC Purchases 44,321 Shares of argenex SE $ARGX

Squarepoint Ops LLC grew its holdings in argenex SE (NASDAQ:ARGX) by 314.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 58,400 shares of the company’s stock after purchasing an additional 44,321 shares during the quarter. Squarepoint Ops LLC’s holdings in argenex were worth $54,182,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ARGX. Valeo Financial Advisors LLC boosted its stake in argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after acquiring an additional 12 shares during the last quarter. CI Investments Inc. raised its position in shares of argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after acquiring an additional 12 shares during the last quarter. Allworth Financial LP boosted its position in shares of argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after purchasing an additional 13 shares during the last quarter. WPG Advisers LLC boosted its position in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares during the last quarter. Finally, NewEdge Advisors LLC grew its stake in shares of argenex by 2.8% during the first quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock worth $382,000 after purchasing an additional 14 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of recent analyst reports. Morgan Stanley raised their target price on argenex from $1,230.00 to $1,250.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a research report on Sunday. Bank of America lifted their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Wedbush reaffirmed an “outperform” rating and issued a $1,150.00 target price on shares of argenex in a research note on Thursday, September 3rd. Finally, Piper Sandler upped their target price on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,158.61.

argenex Price Performance

ARGX opened at $1,007.07 on Wednesday. The company has a market capitalization of $63.00 billion, a price-to-earnings ratio of 38.67, a P/E/G ratio of 1.07 and a beta of 0.47. The business’s 50-day moving average price is $930.46 and its two-hundred day moving average price is $844.09. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. Sell-side analysts anticipate that argenex SE will post 29.13 earnings per share for the current fiscal year.

argenex Company Profile

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies.